Mesoblast/$MESO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mesoblast
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Ticker
$MESO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Melbourne, Australia
Employees
73
ISIN
US5907174016
Website
Mesoblast Metrics
BasicAdvanced
$1.3B
-
-$0.09
2.13
-
Price and volume
Market cap
$1.3B
Beta
2.13
52-week high
$22.00
52-week low
$5.78
Average daily volume
209K
Financial strength
Current ratio
0.958
Quick ratio
0.563
Long term debt to equity
23.029
Total debt to equity
27.34
Interest coverage (TTM)
-2.43%
Profitability
EBITDA (TTM)
-49.425
Gross margin (TTM)
-370.20%
Net profit margin (TTM)
-1,822.77%
Operating margin (TTM)
-906.03%
Effective tax rate (TTM)
-0.12%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-4.85%
Return on equity (TTM)
-21.31%
Valuation
Price to revenue (TTM)
2,076.665
Price to book
3.94
Price to tangible book (TTM)
-15.98
Price to free cash flow (TTM)
-275.239
Free cash flow yield (TTM)
-0.36%
Free cash flow per share (TTM)
-3.82%
Growth
Revenue change (TTM)
-24.07%
Earnings per share change (TTM)
7.13%
3-year revenue growth (CAGR)
-16.86%
10-year revenue growth (CAGR)
-13.26%
3-year earnings per share growth (CAGR)
-15.43%
10-year earnings per share growth (CAGR)
-9.99%
What the Analysts think about Mesoblast
Analyst ratings (Buy, Hold, Sell) for Mesoblast stock.
Bulls say / Bears say
FDA approval of Ryoncil (remestemcel-L) in December 2024 for treating children with steroid-refractory acute graft-versus-host disease positions Mesoblast as a leader in mesenchymal stromal cell therapies, potentially boosting revenue and market share. (Mesoblast)
The FDA's Regenerative Medicine Advanced Therapy designation for Revascor (rexlemestrocel-L) in December 2024 for treating children with congenital heart disease could expedite development and approval processes, enhancing Mesoblast's pipeline value. (Mesoblast)
A 23% reduction in net cash usage for operating activities in FY2024 indicates improved cost management, potentially leading to better financial stability and investor confidence. (StockTitan)
A net loss of $88 million in FY2024, a 7% increase from the previous year, highlights ongoing financial challenges that may concern investors. (StockTitan)
The forecasted breakeven date has been pushed back to 2026, indicating prolonged periods before profitability, which could deter potential investors. (Simply Wall St)
The FDA's Complete Response Letter in August 2023 for the Biologics License Application for remestemcel-L in children with steroid-refractory acute graft-versus-host disease suggests regulatory hurdles that may delay product launches and revenue generation. (Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Mesoblast Financial Performance
Revenues and expenses
Mesoblast Earnings Performance
Company profitability
Mesoblast News
AllArticlesVideos
Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor
Benzinga·1 week ago
Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure
GlobeNewsWire·1 week ago
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mesoblast stock?
Mesoblast (MESO) has a market cap of $1.3B as of July 10, 2025.
What is the P/E ratio for Mesoblast stock?
The price to earnings (P/E) ratio for Mesoblast (MESO) stock is 0 as of July 10, 2025.
Does Mesoblast stock pay dividends?
No, Mesoblast (MESO) stock does not pay dividends to its shareholders as of July 10, 2025.
When is the next Mesoblast dividend payment date?
Mesoblast (MESO) stock does not pay dividends to its shareholders.
What is the beta indicator for Mesoblast?
Mesoblast (MESO) has a beta rating of 2.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.